Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/S ratio is N/A as of 2026-10-06T18:27:13.713Z.
Calculation as of: 2026-10-06T18:27:13.713Z.
Quote observation: 2026-10-06T18:25:07.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 610e9c20fcdf10729c15ba1bd616707a7081826ce2aba31979c935d5001cdfd8
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PS RATIO
N/A
Market Cap
$1.40B
PS Ratio
255.42
TTM Avg
270.55
3Y Avg
122.63
5Y Avg
108.45
Market Cap
$1.43B
PS Ratio
2.00
TTM Avg
3.96
3Y Avg
6.31
5Y Avg
7.98
Market Cap
$1.39B
PS Ratio
N/A
TTM Avg
865.07
3Y Avg
1036.91
5Y Avg
726.94
Market Cap
$1.44B
PS Ratio
0.77
TTM Avg
0.80
3Y Avg
0.61
5Y Avg
0.64
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Kailera Therapeutics, Inc. (KLRA) | $1.41B | N/A | N/A | N/A | N/A |
| The Pennant Group, Inc. (PNTG)vs › | $1.41B | 1.28 | 1.22 | 1.22 | 1.12 |
| AnaptysBio, Inc. (ANAB)vs › | $1.42B | 5.96 | 6.28 | 11.75 | 20.01 |
| Taysha Gene Therapies, Inc. (TSHA)vs › | $1.40B | 255.42 | 270.55 | 122.63 | 108.45 |
| Braveheart Bio, Inc. (BRVE)vs › | $1.43B | N/A | N/A | N/A | N/A |
| Ultragenyx Pharmaceutical Inc. (RARE)vs › | $1.43B | 2.00 | 3.96 | 6.31 | 7.98 |
| Inhibrx Biosciences Inc. (INBX)vs › | $1.39B | N/A | 865.07 | 1036.91 | 726.94 |
| Healthcare Services Group, Inc. (HCSG)vs › | $1.44B | 0.77 | 0.80 | 0.61 | 0.64 |
| Certara, Inc. (CERT)vs › | $1.45B | 3.54 | 3.01 | 4.89 | 7.22 |
| Maze Therapeutics, Inc. (MAZE)vs › | $1.45B | 72.34 | 162.26 | 112.18 | 112.18 |
The four-quarter calculation detail is unavailable for this stored observation.
The current P/S calculation cannot be reconciled from the stored quote and revenue inputs.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
P/S Ratio
N/A
Market Cap / Trailing Twelve-Month Revenue
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
